Are vaccines set for a makeover? Two innovative studies from researchers in Massachusetts demonstrate the creative new approaches that R&D scientists are taking to improve the efficacy – and convenience – of vaccination.
Stephanie Sutton |
At the Forsyth Institute, scientists have developed a new oral system that utilizes the natural bacteria in a patient’s mouth (1). According to Antonio Campos-Neto, Director of the Global Infectious Disease Research Center at the institute, “Commensal non-disease causing oral bacteria are attractive vaccine vector candidates, because they are safe. They are also able to colonize the oral mucosa and they elicit potent mucosal immune responses.”
Campos-Neto and colleagues reported their findings in a recent study where Streptococcus mitis was used as the delivery vehicle for immunization against Mycobacterium tuberculosis. The group generated a recombinant S. mitis (using homologous recombination) that expressed the TB bacteria protein – Ag85b. Tests on animals showed that the vaccine was safe and elicited the production of oral and systemic anti-Ag85b specific IgA and IgG antibodies.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.